Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Phase II Study of Efficacy and Safety of TLL-018 in Moderate-to-Severe CSU Participants With Inadequate Response to Second-Generation H1 Antihistamines

NCT07764003 is registered in ClinicalTrials.gov with Hangzhou Highlightll Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07764003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07764003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Phase II Study of Efficacy and Safety of TLL-018 in Moderate-to-Severe CSU Participants With Inadequate Response to Second-Generation H1 Antihistamines
Lead sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 10, 2026
Completion date
December 31, 2027
Enrollment
140 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria (csu)